Century Therapeutics, Inc. filings document a biotechnology issuer developing iPSC-derived cell therapy programs for autoimmune diseases and cancer, along with the formal records supporting its public-company governance and capital structure. Form 8-K reports include operating and financial results, Regulation FD investor-presentation materials, clinical and regulatory program disclosures, and board composition changes.
Proxy and shareholder-vote materials cover annual meeting matters, board and committee governance, and charter-amendment voting, including reverse-stock-split authority. Capital-structure filings include shelf registration and at-the-market equity offering disclosures for common stock, while cover-page disclosures identify Century as an emerging growth company.
Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger reported a small share disposition related to taxes. On the vesting of restricted stock units, 463 shares of Common Stock were withheld by the company at a price of $2.13 per share to cover tax withholding obligations, leaving him with 3,679,323 shares held directly.
Century Therapeutics filed an 8-K after presenting new preclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at the American Diabetes Association 2026 Scientific Sessions. CNTY-813 uses the company’s Allo-Evasion™ 5.0 immune evasion technology.
In diabetic mouse models, CNTY-813 islet cells rapidly restored normal blood sugar and maintained glucose control for more than eight months, with glucose normalization within 60 minutes on tolerance testing. Safety data showed stable graft morphology, no abnormal outgrowth, and no tumorigenesis across over 140 mice infused with one billion cells.
The company also reported strong in vitro and in vivo immune protection, including preserved C-peptide secretion and glucose tolerance in a humanized allogeneic rejection model, and consistent product quality from its Phase 1 manufacturing process. Century is targeting an IND submission for CNTY-813 in the fourth quarter of 2026 and anticipates initial clinical data in the second half of 2027.
IPSC filed a Form 144 notice proposing the sale of Common stock tied to a Restricted Stock Vesting event on 06/05/2026. The filing also lists prior sales by Gregory Russotti: 479 shares on 03/09/2026 (listed with $1,214.98) and 10,076 shares on 03/12/2026 (listed with $25,685.74). The broker/dealer named is Fidelity Brokerage Services LLC.
IPSC registers the resale of up to 176,086,947 shares of common stock for resale or other disposition by the selling stockholders named in the prospectus supplement.
This supplement substitutes SILV Fund, Ltd. for Point72 Associates, LLC in the selling stockholders table and updates that holder's row to reflect a prior ownership of 7,057,359 shares and a maximum of 3,260,869 shares to be sold under the prospectus. Shares outstanding were 180,102,343 as of March 31, 2026.
Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger had 31,172 shares of Common Stock withheld by the company to cover taxes tied to restricted stock units vesting. After this tax-withholding disposition, he holds 3,679,786 shares of Century Therapeutics Common Stock directly.
Century Therapeutics, Inc. ownership update: Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen report shared voting and dispositive power over 5,964,678 shares of common stock, equal to 3.3% of the class as of March 31, 2026. The filing states these Reporting Persons hold no shares directly and that Point72 Asset Management maintains investment and voting power for an investment fund it manages; Point72 Capital Advisors Inc. is the general partner and Mr. Cohen controls both entities.
Century Therapeutics disclosure: RTW Investments, LP and Roderick Wong report shared beneficial ownership of 13,043,478 shares of Common Stock, representing 7.1% of the class. The percentages assume exercise of warrants to purchase 4,347,826 shares and are calculated using 179,722,750 shares outstanding as of February 28, 2026.
The filing states the RTW Funds have shared voting and shared dispositive power over the reported shares; the filing is made on behalf of the RTW Funds and Dr. Wong as managing partner.
Century Therapeutics reported first quarter 2026 results showing no collaboration revenue compared with $109,164k a year earlier, leading to a net loss. Operating expenses fell to $23,684k from $34,988k as research and development and general and administrative costs both declined.
The company posted a net loss of $21,645k, versus net income of $76,560k in the prior-year quarter, with basic and diluted net loss per share of $0.11 compared with earnings of $0.89. Cash and cash equivalents were $51,048k, and total assets rose to $326,553k with stockholders' equity of $264,744k.
Century Therapeutics, Inc. reported a net loss of $21.6 million for the three months ended March 31, 2026, compared with net income of $76.6 million a year earlier, when results included a large one-time collaboration revenue from Bristol-Myers Squibb.
Collaboration revenue was $0 this quarter versus $109.2 million in the prior-year period. Research and development expenses declined to $17.1 million from $26.6 million, and general and administrative expenses fell to $6.6 million from $8.4 million, reflecting cost controls and portfolio focus.
Cash, cash equivalents and investments totaled about $217.0 million, and management believes this will fund operations into the first quarter of 2029. During the quarter, the company closed a $126.4 million private placement, significantly increasing shares outstanding while supporting development of lead iPSC-derived cell therapy programs CNTY-813, CNTY-308 and CNTY-101.
Century Therapeutics, Inc. Senior Vice President of Finance & Operations Douglas Carr completed an automatic sale of 264 shares of common stock at $2.341 per share. The sale was made solely to cover tax withholding obligations arising from the vesting of restricted stock units and was not at his discretion.
Following this tax-related sale, Carr directly holds 506,997 shares of Century Therapeutics common stock, indicating that the transaction represents a very small portion of his overall equity position.